2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-136922
    Orexin receptor antagonist 2 1457940-75-8 98.08%
    Orexin receptor antagonist 2 (compound 30) is a potent orexin receptor antagonist with pKis of 7.69 and 9.78. Orexin receptor antagonist 2 has the potential for the research of insomnia.
    Orexin receptor antagonist 2
  • HY-137459
    Vocacapsaicin 1931116-86-7 98%
    Vocacapsaicin (CA-008), a proagent of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin can provide meaningful and long-lasting pain relief.
    Vocacapsaicin
  • HY-137572
    (R)-DOI hydrochloride 82864-02-6 99.63%
    (R)-DOI hydrochloride is a selective 5HT2A receptor agonist. (R)-DOI hydrochloride has anti-inflammatory, anti-oxidative stress, and lysosomal function-improving effects. (R)-DOI hydrochloride can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease.
    (R)-DOI hydrochloride
  • HY-13788C
    LY 344864 racemate 186543-64-6 98.07%
    LY 344864 racemate is a 5-HT1F receptor agonist extracted from patent US 5708187 A.
    LY 344864 racemate
  • HY-137951
    Metizolam 40054-68-0 99.30%
    Metizolam, a thienotriazolodiazepine, is the demethylated analogue of Etizolam. Metizolam exhibits psychomotor stabilizing, anxiolytic, sedative, myo-relaxant and amnestic effects.
    Metizolam
  • HY-137961
    Cannabigerol monomethyl ether 29106-17-0 98.04%
    Cannabigerol monomethyl ether is a monomethyl ether derivative of the canonical phytocannabinoids.
    Cannabigerol monomethyl ether
  • HY-137979
    Flunitrazolam 2243815-18-9 99.9%
    Flunitrazolam is an orally active designer Benzodiazepine. Flunitrazolam is biologically toxic, class in psychoactive substances.
    Flunitrazolam
  • HY-138131
    SOD1-Derlin-1 inhibitor-1 840461-03-2 99.93%
    SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1G93A-Derlin-1 complex with an IC50 value of 7.11 μM. SOD1-Derlin-1 inhibitor-1 can be used for the research of amyotrophic lateral sclerosis.
    SOD1-Derlin-1 inhibitor-1
  • HY-138648
    PB1 188714-28-5 99.47%
    PB1 is a potent intracellular disulfide reducing agent with several advantages including good cell permeability, the ability to form a high intracellular concentration gradient, and stability. PB1 is a borane-protected TCEP (tris(2-carboxyethyl)phosphine) analogue. PB1 increases retinal ganglion cells survival after axotomy in vitro at nanomolar and picomolar concentrations. PB1 can be used for the research of neuroprotective.
    PB1
  • HY-138679
    Aberrant tau ligand 2 2417159-58-9 98%
    Aberrant tau ligand 2 (Compound 4-12) is the ligand for tau protein and can be used as target protein ligand for synthesis of PROTAC degrader C004019 (HY-138669).
    Aberrant tau ligand 2
  • HY-138695
    Orexin 2 Receptor Agonist 2 2114324-60-4 98.06%
    Orexin 2 Receptor Agonist 2 is a selective orexin 2 receptor agonist, extracted from patent WO2017135306A1, example 16.
    Orexin 2 Receptor Agonist 2
  • HY-138879
    CP-601927 357425-02-6 98.24%
    CP-601927 is a selective α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist (Ki=1.2 nM; EC50=2.6 μM). CP-601927 shows good brain penetration and antidepressant-like properties.
    CP-601927
  • HY-139331
    20S Proteasome-IN-1 858557-69-4 99.13%
    20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research.
    20S Proteasome-IN-1
  • HY-141495
    (Rac)-Razpipadon 1643462-93-4
    PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC50 of 5.8 nM (Gs-cAMP).
    (Rac)-Razpipadon
  • HY-14149A
    Cisapride monohydrate 260779-88-2 99.87%
    Cisapride monohydrate is an orally and potent 5-HT4 receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut.
    Cisapride monohydrate
  • HY-14151S
    Prucalopride-13C,d3 2140306-00-7 99.0%
    Prucalopride-13C,d3 is the 13C- and deuterium labeled Prucalopride.
    Prucalopride-13C,d3
  • HY-141554
    Dihydrotetrabenazine 3466-75-9 99.23%
    Dihydrotetrabenazine (DHTBZ) is the active metabolite of Tetrabenazine (HY-B0590). Dihydrotetrabenazine is the inhibitor for human vesicular monoamine transporter 2 (VMAT2), that reduces monoamine content in presynaptic neurons, and can be used in movement disorder research.
    Dihydrotetrabenazine
  • HY-141712
    ZA18 2696407-32-4 99.72%
    ZA18 is a selective TRPM2 channel inhibitor, with an IC50 value of 6.2 μM. ZA18 can effectively suppress intracellular Ca2+ overload triggered by TRPM2 channel activation. ZA18 significantly reduce the mortality of SH-SY5Y cells induced by H2O2. ZA18 can be used for the study of ischemia-reperfusion injury, inflammation, or other neurodegenerative diseases.
    ZA18
  • HY-141804
    ER176 1373887-29-6 99.77%
    ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation.
    ER176
  • HY-142110
    LY 78335 39226-94-3 99.19%
    LY 78335 (DCMB) is a brain-penetrant phenylethanolamine-N-methyltransferase (PNMT) inhibitor with a Ki of 0.09 μM. LY 78335 acts as an α₂-adrenoceptor inhibitor with an IC50 of 10 μM. LY 78335 increases spontaneous locomotor activity in rats. LY 78335 increases extracellular concentration of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rat hypothalamus. LY 78335 prevents growth hormone (GH) secretion in rats. LY 78335 can be used for the research of depression.
    LY 78335
Cat. No. Product Name / Synonyms Application Reactivity